Monday - Friday, 6:00 - 7:00 PM ET

Cramer's Lightning Round: Union Pacific is a buy

Published Wed, Jun 11 20256:59 PM EDT

Key Points

It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

BioMarin Pharmaceutical's year-to-date stock performance.

BioMarin Pharmaceutical: "I'm getting tired of the orphan drug model...I don't think it works now."

Union Pacific's year-to-date stock performance.

Union Pacific: "I think it's a buy...I think it's a really good stock to own."

GitLab's year-to-date stock performance.

GitLab: "I was prepared for disappointment and I got it...I just do not want enterprise software. I think they're all too expensive."

ARS Pharmaceuticals' year-to-date stock performance.

ARS Pharmaceuticals: "I like their model...It's a great flier. Someone needs that technology, someone's going to pay for it."

NuScale Power's year-to-date stock performance.

NuScale Power: "...If it does an offering here, that's when I'd buy. I'd wait for the stock offering after what happened with Oklo tonight."

VIDEO5:1205:12

Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer

Jim Cramer's Guide to Investing

Click here to read Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter

Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market.

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com